| Literature DB >> 28079182 |
Wei-Ju Lee1,2,3, Li-Ning Peng1,2,4, Shu-Ti Chiou2,5, Liang-Kung Chen1,4.
Abstract
The effectiveness of established methods for stratifying cardiovascular risk, for example, the Framingham risk score (FRS), may be improved by adding extra variables. This study evaluated the potential benefits of adding physical health indicators (handgrip strength, walking speed, and peak expiratory flow) to the FRS in predicting cardiovascular and all-cause mortality by using a nationwide population-based cohort study data. During median follow-up of 4.1 years, 67 of 911 study subjects had died. In Cox regression analysis, all additional physical health indicators, except walking speed, significantly predicted cardiovascular and all-cause mortality (P < 0.05). Compared with the conventional FRS, c statistics were significantly increased when dominant handgrip strength or relative handgrip strength (handgrip strength adjusted for body mass index), or combination with walking speed or peak expiratory flow were incorporated into the FRS prediction model, both in the whole cohort and also in participants who did not have prevalent cardiovascular diseases at baseline. In conclusion, dominant or relative handgrip strength are simple and inexpensive physical health indicators that substantially improve the accuracy of the FRS in predicting cardiovascular and all-cause mortality among middle-aged and older people.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28079182 PMCID: PMC5227916 DOI: 10.1038/srep40427
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of all participants and sex-specific comparison.
| Characteristic: data values show mean ± standard deviation, or number (%) | Total | Men | Women | p value |
|---|---|---|---|---|
| Total numbers | 911 | 504 | 407 | |
| Age (years) | 65.3 ± 9.3 | 66.2 ± 9.5 | 64.2 ± 8.9 | 0.001 |
| Body mass index (kg/m2) | 24.8 ± 3.4 | 24.6 ± 3.1 | 24.9 ± 3.7 | 0.159 |
| Fasting blood glucose (mg/dl) | 106.7 ± 30.6 | 107.7 ± 31.4 | 105.6 ± 29.5 | 0.291 |
| Serum cholesterol (mg/dl) | ||||
| Total | 198.8 ± 37.9 | 192.5 ± 37.1 | 206.6 ± 37.4 | < 0.001 |
| HDL | 47.9 ± 14.0 | 44.8 ± 12.9 | 51.8 ± 14.2 | < 0.001 |
| Blood pressure (mmHg) | ||||
| Systolic | 139.1 ± 20.3 | 140.3 ± 20.0 | 137.8 ± 20.7 | 0.064 |
| Diastolic | 79.1 ± 11.6 | 80.5 ± 12.2 | 77.3 ± 10.7 | < 0.001 |
| Framingham risk score | 12.3 ± 9.1 | 17.4 ± 7.7 | 6.0 ± 6.3 | < 0.001 |
| High-sensitivity C-reactive protein (mg/l) | 2.6 ± 5.7 | 0.3 ± 0.6 | 0.2 ± 0.5 | 0.188 |
| Dominant handgrip strength (kg) | 27.7 ± 10.2 | 33.8 ± 8.7 | 20.1 ± 6.1 | < 0.001 |
| Relative handgrip strength (kg/BMI) | 2.2 ± 0.8 | 2.7 ± 0.7 | 1.6 ± 0.5 | < 0.001 |
| Walking speed (m/s) | 0.9 ± 0.3 | 0.9 ± 0.3 | 0.8 ± 0.3 | < 0.001 |
| Peak flow (l/min) | 343.4 ± 138.1 | 406.8 ± 139.7 | 265.0 ± 86.2 | <0.001 |
| Smoker | 178 (19.5%) | 10 (2.5) | 168 (33.3) | <0.001 |
| Diabetes | 141 (15.5%) | 70 (17.2) | 71 (14.1) | 0.197 |
| Hypertension | 288 (31.6%) | 127 (31.2) | 161 (31.9) | 0.811 |
| Antihypertensive treatment | 272 (29.9%) | 123 (30.2) | 149 (29.6) | 0.829 |
| Lipid-lowering treatment | 60 (6.6%) | 26 (6.4) | 34 (6.8) | 0.829 |
| Previous cardiovascular disease | 163 (17.9%) | 71 (17.4) | 92 (18.3) | 0.751 |
HDL, high-density lipoprotein; BMI, body mass index.
Area under curve and cut-off points of physical metrics.
| Variable | AUC (95% CI) | Cut-off | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
| High-sensitivity CRP | 0.65 (0.58–0.72) | 3.0 | 43.3 | 81.3 |
| Dominant grip strength | ||||
| Women | 0.74 (0.63–0.85) | 16.0 | 70.0 | 73.6 |
| Men | 0.76 (0.69–0.84) | 28.0 | 68.1 | 75.5 |
| Relative grip strength | ||||
| Women | 0.77 (0.68–0.86) | 1.40 | 80.0 | 67.4 |
| Men | 0.76 (0.68–0.83) | 2.34 | 70.2 | 74.2 |
| Walking speed | 0.73 (0.65–0.81) | 0.8 | 68.7 | 55.5 |
| Peak expiratory flow | 0.66 (0.59–0.73) | 250.0 | 53.7 | 72.9 |
AUC, area under curve; CI, confidence interval; CRP, C-reactive protein.
Age and sex adjusted associations of established risk factors, hs-CRP, and physical indicators with cardiovascular and all-cause mortality.
| Cardiovascular mortality | All-cause mortality | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Hazard ratio | 95% CI | C-statistics | Hazard ratio | 95% CI | C-statistics | ||
| Systolic blood pressure per SD change | 1.8 | 1.2–2.7 | 0.77 | <0.001 | 1.2 | 0.9–1.5 | 0.74 | 0.210 |
| Antihypertensive treatment | 1.4 | 0.6–3.6 | 0.73 | 0.459 | 1.1 | 0.6–1.9 | 0.74 | 0.777 |
| Total cholesterol per SD change | 0.9 | 0.6–1.4 | 0.74 | 0.601 | 1.0 | 0.8–1.3 | 0.74 | 0.909 |
| HDL-cholesterol per SD change | 0.7 | 0.4–1.3 | 0.73 | 0.286 | 0.8 | 0.5–1.0 | 0.73 | 0.007 |
| Lipid-lowering treatment | 2.3 | 0.6–8.3 | 0.73 | 0.202 | 1.9 | 0.8–4.3 | 0.74 | 0.136 |
| Diabetes | 2.0 | 0.7–5.7 | 0.74 | 0.195 | 1.9 | 1.0–3.6 | 0.74 | 0.038 |
| Smoking | 0.9 | 0.3–2.9 | 0.73 | 0.856 | 0.8 | 0.4–1.6 | 0.74 | 0.533 |
| Body mass index per SD change | 1.1 | 0.7–1.8 | 0.74 | 0.597 | 1.1 | 0.8–1.4 | 0.74 | 0.568 |
| Framingham risk score per SD change | 2.4 | 1.3–4.5 | 0.78 | 0.006 | 1.3 | 0.9–1.9 | 0.74 | 0.157 |
| High-sensitivity CRP per SD change | 1.6 | 1.2–2.2 | 0.77 | 0.004 | 1.6 | 1.3–1.9 | 0.77 | <0.001 |
| Dominant handgrip strength per SD change | 0.5 | 0.3–0.9 | 0.77 | 0.012 | 0.4 | 0.3–0.5 | 0.78 | <0.001 |
| Relative handgrip strength per SD change | 0.5 | 0.3–0.8 | 0.79 | 0.010 | 0.4 | 0.3–0.6 | 0.79 | <0.001 |
| Walking speed per SD change | 0.7 | 0.4–1.1 | 0.74 | 0.132 | 0.8 | 0.6–1.0 | 0.74 | <0.083 |
| Peak flow rate per SD change | 0.5 | 0.2–0.9 | 0.78 | 0.016 | 0.5 | 0.4–0.7 | 0.76 | <0.001 |
CI, confidence interval; HDL, high-density lipoprotein; CRP, C-reactive protein.
Hazard ratios for death from all-cause and cardiovascular causes according to physical indicators*.
| Indicators | Entire cohort | Participants without CVD at baseline | ||||||
|---|---|---|---|---|---|---|---|---|
| Cardiovascular death | All-cause death | Cardiovascular death | All-cause death | |||||
| 95% CI | 95% CI | 95% CI | 95% CI | |||||
| Framingham risk score | ||||||||
| 1-SD increase | 2.7 (1.7–4.4) | <0.001 | 1.9 (1.5–2.3) | <0.001 | 1.9 (1.1–3.4) | 0.024 | 1.6 (1.3–2.2) | <0.001 |
| <10% | Reference | Reference | ||||||
| 10%–20% | 2.5 (0.6–10.4) | 0.213 | 1.7 (0.9–3.3) | 0.130 | 1.7 (0.3–8.3) | 0.529 | 2.0 (0.9–4.2) | 0.086 |
| ≥0% | 6.5 (1.8–23.1) | 0.004 | 3.4 (1.9–6.1) | <0.001 | 3.0 (0.7–12.7) | 0.128 | 3.1 (1.5–6.3) | 0.002 |
| High-sensitivity CRP† | ||||||||
| 1-SD increase | 1.7 (1.2–2.3) | 0.001 | 1.5 (1.3–1.8) | <0.001 | 1.7 (1.2–2.5) | 0.007 | 1.4 (1.2–1.7) | 0.001 |
| >3.0 mg/l‡§ | 3.4 (1.4–8.3) | 0.008 | 2.6 (1.6–4.3) | <0.001 | 3.0 (0.9–10.2) | 0.077 | 2.1 (1.1–3.8) | 0.02 |
| Dominant handgrip strength† | ||||||||
| 1-SD increase | 0.4 (0.2–0.8) | 0.004 | 0.4 (0.3–0.6) | <0.001 | 0.4 (0.2–0.8) | 0.007 | 0.4 (0.3–0.6) | <0.001 |
| <14.3 kg women, <22.4 kg men‡ | 4.3 (1.6–11.3) | 0.004 | 3.8 (2.2–6.5) | <0.001 | 7.3 (2.0–26.8) | 0.003 | 5.2 (2.7–10.0) | <0.001 |
| <16.0 kg women <28.0 kg men§ | 4.2 (1.5–11.5) | 0.006 | 3.1 (1.8–5.4) | <0.0001 | 8.5 (2.2–32.2) | 0.002 | 4.1 (2.1–7.9) | <0.0001 |
| Relative handgrip strength* | ||||||||
| 1-SD increase | 0.5 (0.3–0.8) | 0.006 | 0.5 (0.3–0.6) | <0.001 | 0.4 (0.2–0.8) | 0.006 | 0.4 (0.3–0.6) | <0.001 |
| <0.79 women, <1.32 men‡ | 1.1 (0.1–8.6) | 0.914 | 2.3 (1.0–5.2) | 0.050 | 0.0 (0.0–NR) | 0.995 | 2.4(0.8–7.1) | 0.121 |
| <1.40 women, <2.34 men§ | 3.4 (1.2–9.5) | 0.017 | 3.9 (2.2–7.0) | <0.0001 | 6.3 (1.5–26.1) | 0.011 | 4.6(2.3–9.2) | <0.0001 |
| Walking speed† | ||||||||
| 1-SD increase | 0.7 (0.4–1.2) | 0.179 | 0.8 (0.6–1.1) | 0.110 | 0.7 (0.3–1.5) | 0.313 | 0.8(0.6–1.2) | 0.293 |
| <0.8 m/s‡,§ | 1.0 (0.3–2.7) | 0.925 | 1.2 (0.7–2.1) | 0.526 | 0.8 (0.2–3.3) | 0.734 | 1.3(0.6–2.5) | 0.526 |
| Peak expiratory flow† | ||||||||
| 1-SD increase | 0.4 (0.2–0.8) | 0.011 | 0.5 (0.4–0.7) | <0.001 | 0.4 (0.2–0.9) | 0.037 | 0.5(0.4–0.8) | 0.003 |
| <250.0 l/min‡,§ | 3.2 (1.2–8.5) | 0.023 | 2.7 (1.6–4.7) | 0.0003 | 3.3 (0.8–13.5) | 0.104 | 2.6(1.3–5.1) | 0.005 |
CVD, cardiovascular disease; CI, confidence interval; SD, standard deviation; CRP, C-reactive protein; NR, not reached.
*Results were calculated by Cox regression analysis. Data were adjusted for: age at baseline (continuous); sex (binary); systolic blood pressure (continuous); use or nonuse of antihypertensive medication (binary); total cholesterol (continuous); high-density lipoprotein cholesterol (continuous); use or nonuse of lipid lowering medication (binary); presence or absence of diabetes (binary); smoking status (binary).
†Data were adjusted for variables listed in footnote* plus body mass index (continuous).
‡Cut-off values according to previous literature.
§Cut-off values according to this study.
Comparison of discrimination for cardiovascular and all-cause mortality when one, two or three physical health indicators are added to a model including age, sex and the Framingham risk score.
| Indicators | Entire cohort C-statistics (95% CI) for | Participants without CVD at baseline C-statistics (95% CI for: | ||||||
|---|---|---|---|---|---|---|---|---|
| Cardiovascular death | All-cause death | Cardiovascular death | All-cause death | |||||
| Framingham risk score | 0.78(0.66–0.89) | Reference | 0.74(0.68–0.80) | Reference | 0.70(0.50–0.90) | Reference | 0.72(0.65–0.80) | Reference |
| High-sensitivity CRP | 0.83(0.73–0.92) | 0.188 | 0.77(0.71–0.83) | 0.007 | 0.82(0.69–0.94) | 0.250 | 0.75(0.68–0.82) | 0.256 |
| Dominant handgrip | 0.81(0.71–0.91) | 0.310 | 0.78(0.72–0.84) | 0.039 | 0.83(0.75–0.92) | 0.076 | 0.77(0.70–0.85) | 0.068 |
| Relative handgrip | 0.81(0.72–0.90) | 0.123 | 0.79(0.73–0.84) | 0.008 | 0.82(0.72–0.91) | 0.066 | 0.78(0.71–0.85) | 0.043 |
| Walking speed | 0.77(0.66–0.89) | 0.787 | 0.74(0.68–0.80) | 0.952 | 0.71(0.52–0.90) | 0.640 | 0.72(0.65–0.80) | 0.705 |
| Peak expiratory flow | 0.81(0.71–0.91) | 0.157 | 0.76(0.69–0.82) | 0.170 | 0.80(0.67–0.92) | 0.171 | 0.74(0.66–0.82) | 0.491 |
| Dominant handgrip + walking speed | 0.76(0.71–0.82) | 0.008 | 0.78(0.72–0.84) | 0.032 | 0.73(0.66–0.80) | 0.006 | 0.77(0.70–0.85) | 0.068 |
| Dominant handgrip + peak expiratory flow | 0.77(0.71–0.83) | 0.021 | 0.79(0.73–0.85) | 0.0271 | 0.73(0.65–0.81) | 0.011 | 0.78(0.70–0.86) | 0.075 |
| Relative handgrip + walking speed | 0.77(0.71–0.82) | 0.002 | 0.79(0.73–0.84) | 0.008 | 0.72(0.65–0.80) | 0.008 | 0.78(0.71–0.85) | 0.043 |
| Relative handgrip + peak expiratory flow | 0.77(0.72–0.83) | 0.004 | 0.80(0.74–0.85) | 0.006 | 0.73(0.65–0.81) | 0.008 | 0.78(0.71–0.86) | 0.031 |
| Walking speed + peak expiratory flow | 0.74(0.68–0.80) | 0.146 | 0.76(0.69–0.82) | 0.1569 | 0.67(0.59–0.76) | 0.110 | 0.74(0.66–0.82) | 0.460 |
| Dominant handgrip + walking speed + peak expiratory flow | 0.77(0.71–0.83) | 0.018 | 0.79(0.73–0.85) | 0.031 | 0.73(0.65–0.81) | 0.011 | 0.78(0.70–0.86) | 0.083 |
| Relative handgrip + walking speed + peak expiratory flow | 0.77(0.72–0.83) | 0.004 | 0.80(0.74–0.85) | 0.007 | 0.73(0.65–0.81) | 0.008 | 0.78(0.71–0.86) | 0.034 |
CI, confidence interval; CVD, cardiovascular disease; CRP, C-reactive protein.
*All models were adjusted for age and sex. P values are for the comparison with model of physical indicators plus Framingham risk score and model of Framingham risk score.